In the 11 MG patients who were followed, TRAF6 expression was significantly decreased in both CD19+ B cells and CD19+CD27+ memory B cells after treatment (CD19+ B cells: before treatment: 2.30 (1.44, 4.52), after treatment: 0.40 (0.19, 2.48), p = 0.03; CD19+CD27+ B cells: before treatment: 1.71 (0.75, 6.00), after treatment: 0.56 (0.23, 3.06), p < 0.01) (Fig. 3). Here, CD19 is linked to myasthenia gravis.